Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives

Drug-metabolizing enzymes are responsible for the activation or detoxification of cytotoxic drugs. Allelic variants are present with a variable frequency in different populations around the world and have an important role in the therapeutic index of such drugs. It is known that polymorphisms in thiopurine methyltransferase and dihydropyrimidine dehydrogenase have been associated with altered drug metabolism and increased risk of severe toxicity from 6-mercaptopurine and 5-fluorouracil, respectively. Additionally, a variant number of dinucleotide-repeat sequences in the promotor for uridine 5′-diphosphate glucuronosyltransferase 1A1 influences the glucuronidation of SN-38, the active metabolite of irinotecan, which is associated with severe toxicity, including diarrhea and neutropenia. In the same way, polymorphisms in thymidylate synthase have been associated with pyrimidine-associated toxicity and also with response to chemotherapy. The examples shown in this review demonstrate the usefulness of pre-screening patients for well-characterized polymorphism to identify the best-tolerated and most-effective treatment.

[1]  M. Relling,et al.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Ulrich,et al.  Cancer pharmacogenetics: polymorphisms, pathways and beyond , 2003, Nature Reviews Cancer.

[3]  C. Peterson,et al.  Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease. , 2004, Clinical chemistry.

[4]  H. Ishitsuka,et al.  High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Smith,et al.  Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. , 1994, British journal of clinical pharmacology.

[7]  H. McLeod,et al.  Novel thymidylate synthase enhancer region alleles in African populations , 2000, Human mutation.

[8]  H. McLeod,et al.  Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway , 2004, The Pharmacogenomics Journal.

[9]  P. Vreken,et al.  Nomenclature for human DPYD alleles. , 1998, Pharmacogenetics.

[10]  M. Relling,et al.  Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. , 1999, Human molecular genetics.

[11]  H. McLeod,et al.  Known variant DPYD alleles do not explain DPD deficiency in cancer patients. , 2000, Pharmacogenetics.

[12]  E. Marshall.  Preventing Toxicity With a Gene Test , 2003, Science.

[13]  C. Ulrich,et al.  Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  Sharon Marsh,et al.  SNP databases and pharmacogenetics: great start, but a long way to go , 2002, Human mutation.

[15]  M. Durán,et al.  Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[16]  G. M. Taylor,et al.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Ueno,et al.  Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin , 2005, Clinical Cancer Research.

[18]  V. Armstrong,et al.  Phenotypic and Genotypic Analysis of Thiopurine S‐Methyltransferase Polymorphism in the Bulgarian Population , 2003, Therapeutic drug monitoring.

[19]  P. Vreken,et al.  Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W , 1997, Human Genetics.

[20]  J. Edwards,et al.  Extra Adverse drug reactions in hospital patients A systematic review of the prospective and retrospective studies , 2002 .

[21]  Hans R Waterham,et al.  Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. , 2002, The Biochemical journal.

[22]  Howard L McLeod,et al.  Cancer pharmacogenomics: current and future applications. , 2003, Biochimica et biophysica acta.

[23]  Martin R. Johnson,et al.  A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. , 2002, Analytical biochemistry.

[24]  D. J. King,et al.  Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia , 1999, British journal of haematology.

[25]  D. Collier,et al.  The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. , 1999, Pharmacogenetics.

[26]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.

[27]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[28]  P. Vreken,et al.  Dihydropyrimidine dehydrogenase deficiency: A novel mutation and expression of missense mutations in E. coli , 1998, Journal of Inherited Metabolic Disease.

[29]  A. Hall,et al.  The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. , 1998, Blood.

[30]  M. Relling,et al.  Isolation of a human thiopurine S‐methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans , 1998, Clinical pharmacology and therapeutics.

[31]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[32]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[33]  D. Lubarsky,et al.  The Impact of Pharmacogenomics on Postoperative Nausea and Vomiting: Do CYP2D6 Allele Copy Number and Polymorphisms Affect the Success or Failure of Ondansetron Prophylaxis? , 2005, Anesthesiology.

[34]  R. Weinshilboum,et al.  Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model. , 2004, Mayo Clinic proceedings.

[35]  H. McLeod,et al.  Cancer Pharmacogenomics: SNPs, Chips, and the Individual Patient , 2003, Cancer investigation.

[36]  F. Goldwasser,et al.  Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  H. Togari,et al.  Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  P. Vreken,et al.  Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. , 1998, British Journal of Clinical Pharmacology.

[39]  C. Kumana,et al.  An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man. , 1975, British journal of clinical pharmacology.

[40]  Christopher F. Martin,et al.  5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  P. Vreken,et al.  Dihydropyrimidine Dehydrogenase Deficiency , 1998 .

[42]  C. A. Blau,et al.  Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. , 1996, Experimental hematology.

[43]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[44]  D. Sargent,et al.  pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5fu)/cpt-11, 5fu/oxaliplatin (oxal), or Cpt-11/oxal therapy for advanced colorectal cancer (crc): Results from an intergroup trial : 1013 , 2003 .

[45]  M. Kris,et al.  Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[47]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[48]  F. Baas,et al.  Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  W. Evans,et al.  Drug methylation in cancer therapy: lessons from the TPMT polymorphism , 2003, Oncogene.

[50]  A. V. van Kuilenburg,et al.  Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. , 1995, DNA and cell biology.

[51]  M. Durán,et al.  Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism , 1985, Journal of Inherited Metabolic Disease.

[52]  A. Rossi,et al.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. , 2003, Journal of the National Cancer Institute.

[53]  K. Akagi,et al.  Germline Mutation of Dihydropyrimidine Dehydrogenese Gene among a Japanese Population in Relation to Toxicity to 5‐Fluorouracil , 2001, Japanese journal of cancer research : Gann.

[54]  L. Kluijtmans,et al.  Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[56]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[57]  H. McLeod,et al.  Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? , 2000, European journal of cancer.

[58]  O. Dassonville,et al.  [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.

[59]  J. Sludden,et al.  Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. , 1998, British Journal of Cancer.

[60]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[61]  P. Vreken,et al.  Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  R. Kaiser,et al.  Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Eichelbaum,et al.  High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. , 2001, Clinical chemistry.

[64]  C. Ulrich,et al.  Pharmacogenetics and folate metabolism -- a promising direction. , 2002, Pharmacogenomics.

[65]  Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[66]  J. G. Donnelly,et al.  Pharmacogenetics in Cancer Chemotherapy: Balancing Toxicity and Response , 2004, Therapeutic drug monitoring.

[67]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[68]  P. Söderkvist,et al.  Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. , 2004, Pharmacogenetics.

[69]  Martin R. Johnson,et al.  Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  M. Ratain,et al.  Update on pharmacogenetics in cancer chemotherapy. , 2002, European journal of cancer.

[71]  A. Vickers,et al.  The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[72]  R. D. De Abreu,et al.  Genetic polymorphism of thiopurine S-methyltransferase in Argentina , 2003, Annals of clinical biochemistry.

[73]  S. Groshen,et al.  A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. , 2001, Anticancer research.

[74]  M. Tarbit,et al.  Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[75]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[76]  M. Watson,et al.  Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer , 2005, Clinical Cancer Research.

[77]  J. Dow,et al.  Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[78]  W. Evans.  Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy , 2004, Therapeutic drug monitoring.

[79]  S. Groshen,et al.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. , 2001, Cancer research.

[80]  H. McLeod,et al.  Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. , 2005, Seminars in oncology.

[81]  S. Marsh,et al.  Cancer pharmacogenetics , 2004, British Journal of Cancer.

[82]  R. Barale,et al.  Genotype–phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects , 2001, European Journal of Clinical Pharmacology.

[83]  M. Dubinsky.  Optimizing immunomodulator therapy for inflammatory bowel disease , 2003, Current gastroenterology reports.

[84]  R. Matthews,et al.  Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification , 1994, Nature Genetics.

[85]  Mary V. Relling,et al.  Pharmacogenetics and cancer therapy , 2001, Nature Reviews Cancer.

[86]  M. Hiratsuka,et al.  Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. , 2000, Mutation research.

[87]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[88]  D. Nebert,et al.  Pharmacogenomics and “Individualized Drug Therapy” , 2003 .

[89]  Gregory Re,et al.  5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. , 1998 .

[90]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[91]  P. Ueland,et al.  Biological and clinical implications of the MTHFR C677T polymorphism. , 2001, Trends in pharmacological sciences.

[92]  A. V. van Kuilenburg,et al.  Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  G. Morgan,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[94]  B. Burchell,et al.  Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.

[95]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[96]  M. Eichelbaum,et al.  In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. , 1995, Biochemical pharmacology.

[97]  P. Vreken,et al.  Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene , 1997, Journal of Inherited Metabolic Disease.

[98]  S. Daly,et al.  Thermolabile variant of 5, 10-methylenetetrahydrofolate reductaseassociated with low red-cell folates: implications for folate intake recommendations , 1997, The Lancet.

[99]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[101]  Martin R. Johnson,et al.  Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[102]  Benjamin Rs.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .

[103]  W. Evans,et al.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.

[104]  H. Saka,et al.  UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  C. Martín,et al.  Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer , 1997, Anti-cancer drugs.

[106]  V. Heinemann,et al.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995, Seminars in oncology.